BCN Peptides supports IDP-Pharma in the development of a new chemical entity aimed to treat Multiple Myeloma.
The collaboraive project has been granted with funds from the European Union FEDER via ACCIO and its programme “Nuclis d’Innovació Tecnològica”.
![](https://www.bcnpeptides.com/wp-content/uploads/2022/11/logoFeder_01-2.png_496860928-2.png)
![](https://www.bcnpeptides.com/wp-content/uploads/2022/11/logo-vector-accio-2.jpg)